D. Verbeelen

560 total citations
27 papers, 433 citations indexed

About

D. Verbeelen is a scholar working on Nephrology, Pediatrics, Perinatology and Child Health and Nutrition and Dietetics. According to data from OpenAlex, D. Verbeelen has authored 27 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Nephrology, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Nutrition and Dietetics. Recurrent topics in D. Verbeelen's work include Dialysis and Renal Disease Management (5 papers), Aluminum toxicity and tolerance in plants and animals (5 papers) and Pharmacological Effects and Toxicity Studies (5 papers). D. Verbeelen is often cited by papers focused on Dialysis and Renal Disease Management (5 papers), Aluminum toxicity and tolerance in plants and animals (5 papers) and Pharmacological Effects and Toxicity Studies (5 papers). D. Verbeelen collaborates with scholars based in Belgium, United Kingdom and Netherlands. D. Verbeelen's co-authors include Guy Laureys, Jeroen Sonck, Christiane Van Den Branden, J. Sennesael, Marc Jonckheer, Jacques Sennesael, Marina Pauwels, J. Smeyers–Verbeke, Jigang Zhang and Véronique Maes and has published in prestigious journals such as The Lancet, Clinical Chemistry and American Journal of Kidney Diseases.

In The Last Decade

D. Verbeelen

27 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Verbeelen Belgium 12 144 86 64 62 60 27 433
S Biasioli Italy 18 376 2.6× 60 0.7× 60 0.9× 80 1.3× 28 0.5× 55 748
H.-H. Neumayer Germany 11 193 1.3× 41 0.5× 96 1.5× 79 1.3× 59 1.0× 24 560
Donald C. Greenway Canada 13 69 0.5× 41 0.5× 84 1.3× 46 0.7× 14 0.2× 20 645
A. Quintanilla United States 11 103 0.7× 50 0.6× 76 1.2× 23 0.4× 27 0.5× 46 494
Milagros Fernández Lucas Spain 10 181 1.3× 24 0.3× 28 0.4× 59 1.0× 16 0.3× 67 586
B.G. Ellis United Kingdom 14 93 0.6× 23 0.3× 48 0.8× 51 0.8× 19 0.3× 17 652
William B. Blythe United States 12 202 1.4× 63 0.7× 55 0.9× 57 0.9× 19 0.3× 23 725
Zahra Pezeshki Iran 19 109 0.8× 38 0.4× 141 2.2× 56 0.9× 10 0.2× 51 854
A.I. Macdougall United Kingdom 12 76 0.5× 29 0.3× 39 0.6× 124 2.0× 12 0.2× 20 512
L. Löcsey Hungary 11 94 0.7× 63 0.7× 20 0.3× 22 0.4× 11 0.2× 40 402

Countries citing papers authored by D. Verbeelen

Since Specialization
Citations

This map shows the geographic impact of D. Verbeelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Verbeelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Verbeelen more than expected).

Fields of papers citing papers by D. Verbeelen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Verbeelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Verbeelen. The network helps show where D. Verbeelen may publish in the future.

Co-authorship network of co-authors of D. Verbeelen

This figure shows the co-authorship network connecting the top 25 collaborators of D. Verbeelen. A scholar is included among the top collaborators of D. Verbeelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Verbeelen. D. Verbeelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sonck, Jeroen, Guy Laureys, & D. Verbeelen. (2007). The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrology Dialysis Transplantation. 23(3). 966–970. 82 indexed citations
2.
Craemer, Dirk De, et al.. (2001). Angiotensin II Administration Causes Enhanced Expression of Glomerulosclerosis-Related Markers and Decreased Renal Antioxidant Enzyme Activities in Rats. Nephron Experimental Nephrology. 9(2). 125–132. 8 indexed citations
3.
Pauwels, Marina, et al.. (2001). Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrology Dialysis Transplantation. 16(1). 147–150. 55 indexed citations
4.
Branden, Christiane Van Den, Dirk De Craemer, Pieter De Bleser, et al.. (2000). Antioxidant Enzyme Gene Expression in Rats with Remnant Kidney Induced Chronic Renal Failure. Nephron Experimental Nephrology. 8(2). 91–96. 17 indexed citations
5.
Verbeelen, D., et al.. (1998). Enalapril Increases Antioxidant Enzyme Activity in Renal Cortical Tissue of Five-Sixths- Nephrectomized Rats. ˜The œNephron journals/Nephron journals. 80(2). 214–219. 16 indexed citations
6.
Branden, Christiane Van Den, et al.. (1997). Effect of Vitamin E on Antioxidant Enzymes, Lipid Peroxidation Products and Glomerulosclerosis in the Rat Remnant Kidney. Nephron. 76(1). 77–81. 32 indexed citations
7.
Brulez, Harald F. H., Huberta A. T. Dekker, P. L. Oe, et al.. (1996). Biocompatibility of a 1.1 % Amino Acid-Containing Peritoneal Dialysis Fluid Compared to a 2.27% Glucose-Based Peritoneal Dialysis Fluid. Nephron. 74(1). 26–32. 17 indexed citations
8.
Sennesael, Jacques, et al.. (1996). Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. American Journal of Kidney Diseases. 27(5). 701–708. 25 indexed citations
9.
Niepen, Patricia Van der, Jacques Sennesael, & D. Verbeelen. (1995). Kinin kinetics during different dialysis protocols with AN69 dialyser in ACEI-treated patients. Nephrology Dialysis Transplantation. 10(9). 1689–1695. 4 indexed citations
10.
Niepen, Patricia Van der, et al.. (1994). Prevention of anaphylactoid reactions to high-flux membrane dialysis and ACE inhibitors by calcium. Nephrology Dialysis Transplantation. 9(1). 87–89. 4 indexed citations
11.
Sennesael, J., D. Verbeelen, L. Vanhaelst, Romano C. Pirola, & S.R. Bareggi. (1991). Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis. European Journal of Clinical Pharmacology. 41(1). 65–68. 3 indexed citations
12.
Verbeelen, D., et al.. (1989). Vitamin D, Desferrioxamine and Aluminum-Induced Bone Disease in Uremic Rats. ˜The œNephron journals/Nephron journals. 53(1). 54–60. 5 indexed citations
13.
Eeckhout, E., D. Verbeelen, J. Sennesael, L Kaufman, & Marc Jonckheer. (1989). Monitoring of Bone Mineral Content in Patients on Regular Hemodialysis. ˜The œNephron journals/Nephron journals. 52(2). 158–161. 29 indexed citations
14.
Verbeelen, D., Axel Bossuyt, Johan Smitz, et al.. (1989). Hemodynamics of patients with renal failure treated with recombinant human erythropoietin.. PubMed. 31(1). 6–11. 27 indexed citations
15.
Verbeelen, D., et al.. (1988). The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.. PubMed. 2(2). 67–72. 7 indexed citations
16.
Verbeelen, D., D. Hauglustaine, & Jacques Sennesael. (1988). Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.. PubMed. 33(1-2). 60–7. 2 indexed citations
17.
Sennesael, J. & D. Verbeelen. (1986). Treatment of dialysis resistant hypertension with enalapril.. PubMed. 41(5). 367–71. 1 indexed citations
18.
Smeyers–Verbeke, J. & D. Verbeelen. (1985). Determination of aluminum in bone by atomic absorption spectroscopy.. Clinical Chemistry. 31(7). 1172–1174. 7 indexed citations
19.
Verbeelen, D., et al.. (1984). Reversible acute on chronic renal failure during captopril treatment.. BMJ. 289(6436). 20–21. 5 indexed citations
20.
Cundy, Tim, et al.. (1983). SERUM ALUMINIUM MEASUREMENTS IN RENAL BONE DISEASE. The Lancet. 321(8334). 1168–1169. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S Biasioli Breakdown of academic impact, for papers by H.-H. Neumayer Breakdown of academic impact, for papers by Donald C. Greenway Breakdown of academic impact, for papers by A. Quintanilla Breakdown of academic impact, for papers by Milagros Fernández Lucas Breakdown of academic impact, for papers by B.G. Ellis Breakdown of academic impact, for papers by William B. Blythe Breakdown of academic impact, for papers by Zahra Pezeshki Breakdown of academic impact, for papers by A.I. Macdougall Breakdown of academic impact, for papers by L. Löcsey
Rankless by CCL
2026